OTC$ZOMDF

Zomedica Corp · Q2 2024 earnings

Q2 2024 earnings · · Investor relations

Briefing

ZOMDF Q2 2024 — n/d revenue, 16.00 EPS

The change in presentation had no effect on the reported results of operations and does not affect previously reported cash flows from operating activities in the c. Zomedica Corp reported Q2 2024 results. Diluted EPS came in at $16.00. Net income of $33K. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.

  • Diluted EPS: $16.00.
  • Net income: $33K.
  • Filed on Form 10-Q (accession 0001558370-24-012228).

Headline financials

Total Revenue

$6.13M

Previous: $6.02M+1.8%
EPS (adj)

-$0.01

Previous: -$0.01-100.0%
Capital Expenditures

-$3.56M

Previous: -$143K-2388.8%
Free Cash Flow

-$17.9M

Previous: -$8.08M-121.2%
Net Income

-$23.9M

Previous: -$5.25M-355.9%
Operating Income

-$25.1M

Previous: -$6.74M-271.8%
Gross Profit

$4.36M

Previous: $4.05M+7.8%
R&D Expense

$1.51M

No prior period
Stock-Based Comp

$859K

Previous: $1.73M-50.2%

Revenue & EPS history

Zomedica · Revenue · Quarterly

$6.13M

Q2 2024+1.8%vs Q2 2023
Beat estimate in 3 of 10 quarters(30%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2024

Historical avgQ2 2024

-1.2%

Avg return

Earnings day

+2.3%

Avg return

5 days after

-1.6%

Avg return

30 days after

27%

9 / 33 earnings

Positive

+41.0%

Q4 2024

Best reaction

-16.9%

Q1 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-8.2%-4.0%-5.1%
Q3 2025+1.3%+26.3%+50.0%
Q1 2025-16.9%-20.3%-22.0%
Q4 2024+41.0%+113.9%+41.7%
Q3 2024-1.4%+14.8%+3.3%
Q2 2024-5.3%-11.6%-14.8%
Q1 2024-16.8%-11.0%-9.1%
Q4 2023-4.0%-4.1%-2.7%
Q3 2023-4.4%-7.2%-6.7%
Q2 2023-2.3%-3.9%-12.2%
Q1 2023-8.8%-8.2%-10.5%
Q4 2022-4.3%-16.5%-10.7%
Q3 2022-5.3%-10.0%-19.6%
Q2 2022-10.3%-28.8%-38.2%
Q1 2022-5.5%+5.3%+28.7%
Q4 2021+3.1%-4.7%-6.4%
Q3 2021-2.2%-6.6%-30.0%
Q2 2021-10.3%-19.3%+2.9%
Q1 2021-15.3%-8.2%+11.4%
Q4 2020+11.4%+9.7%-8.6%
Q3 2020+19.7%+112.7%+106.3%
Q2 2020-2.8%-14.1%-28.8%
Q1 2020+14.6%-1.7%-12.3%
Q4 2019-0.0%-18.0%-32.8%
Q3 2019-2.4%+0.6%+0.6%
Q2 2019+0.0%+0.0%+68.0%
Q1 2019-2.0%-6.9%-7.8%
Q4 2018+2.0%+2.0%-66.6%
Q3 2018-7.5%-8.6%-15.5%
Q2 2018-3.2%-1.4%+0.9%
Q1 2018+0.0%
Q4 2017+0.7%
Q3 2017+7.0%
Q2 2017
Q1 2017
Q4 2016
Q3 2016
Q2 2016
Q1 2014
Q4 2015
Q3 2015
Q2 2015
Q1 2013
Q4 2013
Q3 2013
Q2 2013

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro